Physician profile
Amarnauth Singh
NPI 1639170764
$19,843.60
in general payments reported to CMS, 2019-2025
27 companies · $4,201 in 2025
The $4,201 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,004 · 2020: $3,155 · 2021: $908 · 2022: $1,513 · 2023: $3,091 · 2024: $1,972 · 2025: $4,201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,183 · Travel and Lodging: $2,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,183.45 |
| Travel and Lodging | $2,080.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $6,112.81 | 2019-2025 | Aveir, Mitraclip, Allure Quadra |
| Medtronic, INC. | $3,534.58 | 2021-2025 | Azure Xt Dr Mri Surescan, Micra, Na |
| Biosense Webster, INC. | $3,325.62 | 2019-2025 | Carto 3, Qdot Micro Catheter |
| Boston Scientific Corporation | $2,251.76 | 2019-2025 | Farapulse, General - Brady, Rhythmia Mapping System |
| Medtronic Vascular, INC. | $1,269.40 | 2019 | |
| Biotronik INC. | $832.65 | 2020-2024 | Amvia Edge |
| Cardiva Medical, INC. | $536.25 | 2022-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade 6/7f Vcs |
| Medical Device Business Services, INC. | $528.03 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $212.92 | 2019-2023 | Eliquis |
| Elutia, INC. | $184.31 | 2021-2025 | Ecm Patch,Pouch |
| Novartis Pharmaceuticals Corporation | $150.45 | 2021-2023 | |
| Acutus Medical, INC. | $145.22 | 2022 | |
| Impulse Dynamics (USA) INC. | $124.18 | 2022 | |
| Bardy Diagnostics, INC. | $95.00 | 2019-2021 | |
| Atricure, INC. | $90.59 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $87.64 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $83.36 | 2023-2024 | Assure Wcd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $69.88 | 2019-2021 | |
| Amgen INC. | $47.72 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $35.69 | 2022 | |
| Pfizer INC. | $31.26 | 2019-2023 | |
| Glaxosmithkline, LLC. | $17.62 | 2025 | Nucala |
| Novo Nordisk INC | $17.08 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.61 | 2019 | |
| Esperion Therapeutics, INC. | $15.10 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $14.94 | 2022 | |
| Abiomed | $13.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amarnauth Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.